Year: 2020

Medexus Reaches 50% Enrollment in IXINITY® Phase 4 Clinical Trial Targeting Label Expansion for Pediatric Hemophilia B Patients

Written by Customer Service on November 16, 2020. Posted in Mergers And Acquisitions.

TORONTO, CHICAGO and MONTREAL, Nov. 16, 2020 (GLOBE NEWSWIRE) — Medexus Pharmaceuticals Inc. (the “Company” or “Medexus”) (TSXV: MDP, OTCQX: MEDXF) today announced it has reached the 50% enrollment target in its Phase 4 clinical trial investigating IXINITY® as a prophylactic treatment for pediatric patients under 12 years of age with hemophilia B, a hereditary bleeding disorder characterized by a deficiency of clotting factor IX. IXINITY is an FDA approved intravenous recombinant factor IX therapeutic for use in patients 12 years of age or older with hemophilia B.On February 28, 2020, Medexus announced the acquisition of the worldwide rights to the commercial hematology asset, IXINITY®, from Aptevo Therapeutics, Inc. (NASDAQ: APVO). In January 2020, Aptevo had already commenced dosing patients in a Phase 4 clinical trial to evaluate...

Roth CH Acquisition I to Combine With PureCycle Technologies, Accelerating a Revolution in Plastics Recycling Through Impact Investing

Written by Customer Service on November 16, 2020. Posted in Mergers And Acquisitions.

ONE GOAL: A PURE PLANETTHE MISSION: SOLVING THE MASSIVE ENVIRONMENTAL PROBLEM CREATED BY PLASTIC WASTE IN LANDFILLS AND OCEANS, ENABLING PARTNERS TO MEET SUSTAINABILITY GOALSA REVOLUTIONARY AND PROPRIETARY COST-EFFECTIVE METHOD TO RECYCLE WASTE POLYPROPYLENE TO VIRGIN-LIKE RESINSUPPORTED BY GLOBAL COMMERCIAL PARTNERS: PROCTER & GAMBLE, MILLIKEN & COMPANY, TOTAL, L’ORÉAL, APTAR,RAVAGO AND BMW I VENTURESTRANSACTION INCLUDES $90 MILLION IN EQUITY PRIVATE PLACEMENTS AND A $250 MILLION FULLY-COMMITTED PIPE ANCHORED BY SYLEBRA CAPITAL AND LEADING ENDOWMENT & PENSION FUNDS AND GLOBAL FAMILY OFFICES– Estimated post-transaction equity value of approximately $1.2 billion and gross cash proceeds of approximately $700 million– PureCycle recently completed approximately $300 million in municipal bond and debt offerings–...

AppHarvest to Participate in Goldman Sachs SUSTAIN Fall Symposium on November 17, 2020

Written by Customer Service on November 16, 2020. Posted in Mergers And Acquisitions.

MOREHEAD, Ky., Nov. 16, 2020 (GLOBE NEWSWIRE) — AppHarvest (“the Company”), a registered benefit corporation and Certified B Corp that is a developer and operator of large-scale, high-tech controlled environment indoor farms, today announced that Jonathan Webb, the Company’s Founder and Chief Executive Officer, will participate in the ESG in Agriculture panel at the Goldman Sachs SUSTAIN Fall Symposium being held virtually on Tuesday, November 17, 2020. The Company will also be participating in virtual investor meetings.The ESG in Agriculture panel is scheduled for 9:00 a.m. Eastern and will be moderated by Sandra Lawson, Head of SUSTAIN Strategy, Goldman Sachs. This panel will be webcast live and can be accessed through the following link: https://event.webcasts.com/starthere.jsp?ei=1397044&tp_key=6b9e8a14a0.On September 29,...

Merus to Present at the Jefferies Virtual London Healthcare Conference

Written by Customer Service on November 16, 2020. Posted in Public Companies.

UTRECHT, The Netherlands and CAMBRIDGE, Mass., Nov. 16, 2020 (GLOBE NEWSWIRE) — Merus N.V. (Nasdaq:MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics™), today announced that Bill Lundberg, M.D., President and Chief Executive Officer, will participate in a fireside chat at the Jefferies Virtual London Healthcare Conference on Tuesday, November 17, 2020 at 14:40 p.m. GMT/9:40 a.m. ET.A live webcast of the presentation will be available on the Investors page of the Company’s website, http://www.merus.nl/. An archived presentation will be available on the Merus website for a limited time.About MerusMerus is a clinical-stage oncology company developing innovative full-length human bispecific and trispecific antibody therapeutics, referred to as Multiclonics®....

Security National Financial Corporation Reports Financial Results for the Quarter Ended September 30, 2020

Written by Customer Service on November 16, 2020. Posted in Public Companies.

SALT LAKE CITY, Nov. 16, 2020 (GLOBE NEWSWIRE) — Security National Financial Corporation (SNFC) (NASDAQ symbol “SNFCA”) announced financial results for the quarter ended September 30, 2020.For the three months ended September 30, 2020, SNFC’s after-tax earnings from operations increased 710.2% from $3,617,000 in 2019 to $29,305,000 in 2020, on a 94.0% increase in revenues to $146,205,000. SNFC’s after tax earnings for the nine months ended September 30, 2020 increased 468.1% to $51,286,000 from $9,028,000 in 2019.Scott M. Quist, President of the Company, said, “For the quarter, revenues increased 94%, profitability increased 700%, and YTD we have a 26% return on equity. I believe our third quarter is the best operational third quarter ever for each of our business segments. Those are spectacular results that have been...

Key Energy Services Reports Third Quarter 2020 Earnings

Written by Customer Service on November 16, 2020. Posted in Public Companies.

HOUSTON, Nov. 16, 2020 (GLOBE NEWSWIRE) — Key Energy Services, Inc. (“Key” or the “Company”)(OTC: KEGX) today reported third quarter 2020 consolidated revenues of $42.9 million and a net loss of $3.9 million, or $(0.28) per basic share, as compared to consolidated revenues of $34.8 million and a net loss of $19.1 million, or $(1.39) per basic share, for the second quarter of 2020. The results for the third quarter of 2020 include: (1) severance and restructuring related expense of $0.3 million, or $(0.02) per basic share, related to the Company’s ongoing cost reduction efforts and the first quarter debt restructuring; (2) a gain of $8.0 million, or $0.58 per basic share, related to a favorable settlement of a legal matter; (3) gains on the sale of assets of $0.5 million, or $0.04 per basic share; (4) non-recurring professional fees...

Cocrystal Pharma Reports Third Quarter 2020 Financial Results and Provides Update on Antiviral Programs

Written by Customer Service on November 16, 2020. Posted in Public Companies.

– Continued progress of COVID-19 development programs with additional preclinical studies of coronavirus protease inhibitors (3CL) underway and lead preclinical molecule selection expected by year end –– Ongoing Merck collaboration to discover and develop influenza A/B antiviral agents –– Continued advancement of wholly owned Influenza A development program and IND enabling studies towards Phase 1 clinical study in 2021 –– Successful completion of strategic financing fuels expansion of COVID-19 and Influenza A development programs –BOTHELL, WA, Nov. 16, 2020 (GLOBE NEWSWIRE) — Cocrystal Pharma, Inc. (NASDAQ: COCP), (“Cocrystal” or the “Company”), a clinical stage biotechnology company discovering and developing novel antiviral therapeutics, today announced its financial results for the quarter ended September 30, 2020 and provided...

Proofpoint Named Best Overall Enterprise Email Security Solution Provider of the Year

Written by Customer Service on November 16, 2020. Posted in Public Companies.

SUNNYVALE, Calif., Nov. 16, 2020 (GLOBE NEWSWIRE) — Proofpoint, Inc. (NASDAQ: PFPT), a leading cybersecurity and compliance company, today announced that it has been named the winner of the “Overall Enterprise Email Security Solution Provider of the Year” award in the fourth annual CyberSecurity Breakthrough Awards program conducted by CyberSecurity Breakthrough, a leading independent market intelligence organization that recognizes the top companies, technologies and products in the global information security market today.“Proofpoint is a pioneering leader in the cybersecurity industry and their continued commitment to innovation and breakthrough detection and protection techniques are unparalleled,” said James Johnson, managing director, CyberSecurity Breakthrough. “We fully anticipate that business email compromise (BEC) and...

Aeterna Zentaris Amends License Agreement with Novo Nordisk for Commercialization and Development of Macimorelin

Written by Customer Service on November 16, 2020. Posted in Public Companies.

– Company to receive upfront payment of €5 million replacing a later stage regulatory approval milestone of U.S.$5 million – Novo Nordisk committing to fund €9 million of the budgeted AEZS-130-P02 (“Study P02”) clinical trial costs for childhood-onset growth hormone deficiency expected to be initiated in Q1 2021CHARLESTON, S.C., Nov. 16, 2020 (GLOBE NEWSWIRE) — Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company commercializing and developing therapeutics and diagnostic tests, today announced that, through a wholly-owned subsdiary, it has entered into an amendment (the “Amendment”) of its existing License Agreement with Novo Nordisk Biopharm Limited (“NNBL”) related to the development and commercialization of macimorelin.Under the terms of the original...

Kyber Data Science Announces New Senior Hires

Written by Customer Service on November 16, 2020. Posted in Public Companies.

NEW YORK, Nov. 16, 2020 (GLOBE NEWSWIRE) — Kyber Data Science, LLC (“Kyber”), a subsidiary of Cowen Inc. (NASDAQ:COWN) (“Cowen”), today announced several new senior hires who have recently joined the company, and the promotion of Brian Engelbert to COO of Kyber.Kyber is focused on developing and selling unique and proprietary datasets to institutional investors. Most recently, Kyber unveiled a nationally-representative health care claims and electronic medical records data product that enables timely and accurate analyses across health care subsectors including drug, medical device, diagnostics, and health care services companies. Transaction-level data allow customers to develop a large number of key performance indicators, and drive granular insights into the intricacies of product revenue and disease dynamics.“Reflecting its...

Year: 2020

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals